Ayush Ministry Clarifies No Further Retention Or Renewal Fees After One Time Registration Of ASU Products

New Delhi : Following its move to amend rules on manufacturing of Ayurveda, Siddha and Unani (ASU) drugs through a notification in October this year, the Ministry of Ayush has clarified to the State Licensing Authorities (SLAs) that there will be no further retention or renewal fees after the one time registration of products, as specified in the notification.

In a clarification to the SLAs this month, the Ministry communicated that the manufacturing units of the ASU drugs will be subjected to inspection in a randomised manner every five year while previously this duration of inspection was twice a year. The amendments, under the Drugs (4th Amendment) Rules, 2021, notified on October 1, are aimed to reduce the compliance burden and facilitate ease of doing business.

Through the notification, the Ministry has fixed a one time registration fee as Rs. 2,000 for any number of classical or generic ASU drugs and Rs. 3,000 for the first ten proprietary products and after the said ten products, an additional fee of Rs. 2,000 per product. For existing license holders this fee for one time registration is Rs. 1,000 for any number of classical/generic ASU drugs and Rs. 1,000 for the first ten proprietary products and after that, an additional fee of Rs. 1,000 per product.

“It is to be noted that there will be no further retention or renewal fees thereafter,” said the letter from the Ministry to the SLAs.

“The license of the ASU drugs have been made perpetual i.e. with one time registration fee the license of the product will be valid lifetime subject to online submission of self compliance declaration every year or unless suspended or cancelled. While prior to the notification, it had a validity period of five years,” it said.

The mode of online payment is not at present integrated on the e-aushadhi portal and all submission of fees is through the existing challan system and the receipt of the same is uploaded on the portal for further processing of the application.

“Under Form 25D and 25E it is mandatory for the licensing authority to mention the names of drugs categorised as per Schedule T (each item to be separately specified) with specific Product Code/QR Code for each approved drug,” it added. The fees over and above the first 10 products of patent and proprietary category under the relevant rules will be accordingly calculated for approvals on or after October 1, 2021, said the clarification.

The Ministry has made the process of grant license to manufacture ASU drugs swift, paperless and more transparent by making the license application system online. However, for six months from the date of gazette notification, both online and offline application process will co-exist before it turns completely online.

The amendment also inserted a form for Application for the Certificate of Good Manufacturing Practices (GMP) for Ayurvedic, Siddha or Unani drugs manufacturing units with fees of Rs. 5,000. The applicants will only have to get their GMP certification validated every five years to keep their license in force. The GMP certificate can also be retained with submission of retention fee of Rs. 1,000 every year.

The maximum time in granting the license to manufacture ASU drugs has been reduced from three months to two months, through the amendment.

Issuance of free sale certificate has been made online and non conviction certificate also moved online with submission of notarised affidavit. The validity of non conviction certificates has been increased from six months to one year.

The notification has no retrospective effect and is applicable prospectively. Those who have applied for the licence before October 1, 2021, along with the old fees structure may be considered according to the rates/retirements prevalent on the date of applications. In such cases while issuing a license the date of application may also be mentioned prominently.

  • Related Posts

    The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

    NEW DELHI: Medical technology innovation is entering a new phase, with advanced cardiac implants, incisionless brain surgery, blood-based cancer screening, smart insulin delivery and real-time kidney-function monitoring among the technologies…

    Three arrested after liquor bottles found at pharma firm

    Patna: Three people were arrested and sent to jail after a large quantity of liquor bottles was found at Cellulas Pharma Private Limited in Kankarbagh during a raid by the…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

    The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

    Three arrested after liquor bottles found at pharma firm

    Three arrested after liquor bottles found at pharma firm

    NEXUS 2026 brings pharma experts together to explore next generation analytical technologies

    NEXUS 2026 brings pharma experts together to explore next generation analytical technologies

    National Formulary of India 2026 Lists Unapproved Drugs; DCGI Seeks Urgent Explanation from IPC Over Regulatory Discrepancy

    National Formulary of India 2026 Lists Unapproved Drugs; DCGI Seeks Urgent Explanation from IPC Over Regulatory Discrepancy

    Six leading mental health organisations unite to launch ‘Humanising Medicine India Initiative’ on World Mental Health Day

    Six leading mental health organisations unite to launch ‘Humanising Medicine India Initiative’ on World Mental Health Day

    Cancer Drug Prices May Fall By Up To 70% As Government Caps Trade Margins: Sources

    Cancer Drug Prices May Fall By Up To 70% As Government Caps Trade Margins: Sources